Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. The company was founded in 1998 and is headquartered in Berlin, Germany.
Metrics to compare | ECXk | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipECXkPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.4x | −5.3x | −0.6x | |
PEG Ratio | 0.00 | −0.12 | 0.00 | |
Price/Book | −0.1x | 2.1x | 2.6x | |
Price / LTM Sales | 8.4x | 5.6x | 3.2x | |
Upside (Analyst Target) | - | 0.0% | 47.5% | |
Fair Value Upside | Unlock | 7.7% | 6.7% | Unlock |